1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Jacobson Pharma Corporation Limited

Jacobson Pharma Corporation Limited

2633.HK
Jacobson Pharma Corporation LimitedHK flagHong Kong Stock Exchange
1.09
HKD
+0.01
- -
2.18BMarket Cap
Jacobson Pharma Corporation Limited
2633.HK
(Hong Kong Stock Exchange)

Recent

price

1.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.53
0.54
0.83
0.8
0.85
0.77
0.79
0.75
0.83
0.66
0.76
0.79
Revenue per Share
0.1
0.06
0.11
0.11
0.11
0.13
0.11
0.09
0.09
0.13
0.14
0.15
Basic EPS, GAAP
-0.03
-0.1
0.07
0.05
0.09
0.18
0.14
0.18
0.18
0.3
0.18
0.14
Free Cash Flow per Basic Share
- -
0.01
- -
0.15
0.02
0.05
0.05
0.03
0.03
0.05
0.05
0.03
Dividend per Share
0.42
0.46
0.59
0.6
0.6
0.66
0.71
0.65
0.73
0.78
0.53
0.6
Book Value per Share
0.31
0.33
0.4
0.45
0.51
0.84
0.65
0.79
0.86
1.01
1.02
1.04
Tangible Book Value per Share
1,750
1,750
1,309
1,574
1,816
1,931
1,983
1,916
1,916
1,911
1,920
1,986
Basic Weighted Avg Shares
926
948
1,084
1,256
1,549
1,478
1,571
1,446
1,596
1,268
1,468
1,577
Sales/Revenue/Turnover
17.03
14.02
17.26
17.8
17.98
22.56
18.33
16.22
13.81
21.31
19.63
23.4
Operating Margin (%)
44
53
70
82
112
116
171
192
193
184
142
144
Depreciation Expense
172
102
146
179
202
251
216
174
178
251
267
301
Net Income, GAAP
14.86
16.28
16.58
18.07
18.44
17.96
17.47
15.53
18.89
17.17
17.45
19.48
Effective Tax Rate (%)
18.61
10.75
13.43
14.28
13.06
16.95
13.72
12.01
11.14
19.8
18.19
19.08
Profit Margin (%)
-44
-256
-317
-225
-220
190
443
287
352
1,101
592
485
Working Capital
7
1
1
- -
1
372
1,062
927
764
1,255
610
512
LT Debt
917
1,007
956
1,772
2,008
2,687
2,606
2,860
2,958
3,257
2,396
2,477
Total Equity
- -
8.18
10.78
8.87
7.46
7.43
5.76
4.51
4.01
4.83
5.91
9.22
Return on Invested Capital (%)
- -
7.64
10.84
11.97
10.83
11.67
9.01
5.75
5.67
7.84
11.41
17.64
Return on Capital (%)
- -
13.24
18.46
21.03
19.87
21.2
16.15
13.09
13.41
17.39
21.28
27.13
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.47%
0.05%
3.38%
Free Cash Flow
8.62%
6.08%
-21.55%
Net Income, GAAP
13.19%
8.63%
12.69%
Sales/Revenue/Turnover
6.03%
1.01%
7.43%
Total Cash Common Dividend
1,315.7%
-0.07%
-36.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,468
2025
- -
- -
- -
- -
1,577
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.03
2026
- -
- -
- -
- -
- -
Similar Companies
China Pharma Holdings, Inc. (CPHI)
Shandong Xinhua Pharmaceutical Company Limited (0719.HK)
Gabather AB (publ) (GABA.ST)
PLx Pharma Inc. (PLXP)
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ)
Neuland Laboratories Limited (NEULANDLAB.BO)
Business
Jacobson Pharma Corporation Limited is a prominent pharmaceutical enterprise, vertically integrated for the research, development, manufacturing, distribution, and commercialization of essential and specialty medicines. The company serves healthcare professionals and patients across Hong Kong, Mainland China, Macau, Singapore, and other international markets. Its extensive portfolio of generic drugs addresses a wide array of therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, respiratory, musculoskeletal, genito-urinary, endocrine and metabolic, dermatological, anti-allergics, and anti-infective conditions. Notable developments include the broadening market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong for acute promyelocytic leukemia, expanding into Southeast Asia. While historically involved in branded healthcare products and proprietary Chinese medicines, the branded healthcare segment's operations were classified as discontinued for the fiscal year ended March 31, 2024. The company continues to strengthen its core through a robust R&D pipeline, comprising 219 products as of March 2025, and strategic in-licensing agreements for 20 high-performing specialty drugs across immunology, oncology, cardiology, neurology, and rare diseases. Jacobson Pharma distributes its pharmaceutical offerings to public and private healthcare sectors, encompassing hospitals, clinics, licensed pharmacies, private medical practitioners, and various retail and trading partners. The firm reported total revenue of approximately HK$1,576.9 million for the year ended March 31, 2025, with profit from continuing operations increasing by 43.1% to HK$300.8 million, reflecting sustained growth and operational efficiency. In February 2025, the company launched supply chain liaison services for Axicabtagene Ciloleucel, a CAR-T therapy, in partnership with Shanghai Fosun Pharmaceutical. A new smart pharmaceutical manufacturing facility is also under development at Tai Po InnoPark, with trial production anticipated in late 2026. Incorporated in 2016, the company maintains its headquarters in Kwun Tong, Hong Kong, and operates as a subsidiary of Kingshill Development Limited.